- Home
- FRAF vs IMMP Comparison
FRAF vs IMMP Comparison
Compare FRAF & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRAF
- IMMP
- Stock Information
- Founded
- FRAF 1906
- IMMP 1987
- Country
- FRAF United States
- IMMP Australia
- Employees
- FRAF N/A
- IMMP N/A
- Industry
- FRAF Major Banks
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- FRAF Finance
- IMMP Health Care
- Exchange
- FRAF Nasdaq
- IMMP Nasdaq
- Market Cap
- FRAF 212.1M
- IMMP 251.8M
- IPO Year
- FRAF N/A
- IMMP N/A
- Fundamental
- Price
- FRAF $45.43
- IMMP $1.86
- Analyst Decision
- FRAF
- IMMP Buy
- Analyst Count
- FRAF 0
- IMMP 1
- Target Price
- FRAF N/A
- IMMP $7.00
- AVG Volume (30 Days)
- FRAF 17.1K
- IMMP 93.6K
- Earning Date
- FRAF 10-21-2025
- IMMP 10-21-2025
- Dividend Yield
- FRAF 2.91%
- IMMP N/A
- EPS Growth
- FRAF 5.82
- IMMP N/A
- EPS
- FRAF 3.29
- IMMP N/A
- Revenue
- FRAF $74,998,000.00
- IMMP $3,306,742.00
- Revenue This Year
- FRAF N/A
- IMMP $16.82
- Revenue Next Year
- FRAF N/A
- IMMP N/A
- P/E Ratio
- FRAF $13.81
- IMMP N/A
- Revenue Growth
- FRAF 8.15
- IMMP 31.28
- 52 Week Low
- FRAF $28.01
- IMMP $1.32
- 52 Week High
- FRAF $49.42
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- FRAF 41.37
- IMMP 61.34
- Support Level
- FRAF $44.90
- IMMP $1.64
- Resistance Level
- FRAF $48.60
- IMMP $1.89
- Average True Range (ATR)
- FRAF 0.69
- IMMP 0.08
- MACD
- FRAF -0.59
- IMMP 0.02
- Stochastic Oscillator
- FRAF 11.73
- IMMP 86.21
About FRAF Franklin Financial Services Corporation
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.